Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study

@article{Jacobsen2014BrainAA,
  title={Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study},
  author={Cecilie Jacobsen and Jesper Hagemeier and Kjell Morten Myhr and Harald I. Nyland and Kirsten Lode and Niels P Bergsland and Deepa P. Ramasamy and Turi O. Dalaker and Jan P. Larsen and Elisabeth Farbu and Robert Zivadinov},
  journal={Journal of Neurology, Neurosurgery \& Psychiatry},
  year={2014},
  volume={85},
  pages={1109 - 1115}
}
Objectives To identify MRI biomarkers associated with long-term disability progression in patients with multiple sclerosis (MS), and to define the rate of evolution of global, tissue-specific and regional atrophy in patients with MS over long-term. Methods MRI of the brain and clinical neurological assessment was performed in 81 patients at time of first visit and after 5 and 10 years of follow-up. MRI was acquired on 1.5 T scanners. T1-lesion and T2-lesion volumes (LVs) were calculated. Global… 
A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients
TLDR
WB and cortical atrophy, and enlargement of vCSF spaces are associated with development of CDP on serial yearly MRI assessments over a period of 10 years.
Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations
TLDR
Lower BPF and WMF 15 years after CIS are associated with previous markers of inflammatory disease, and are significantly associated with being male, presenting 3–4 Barkhof criteria at baseline, presenting a second relapse, and with a decision to start treatment.
Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study
TLDR
Over 10 years of follow-up, disability progression in MS is related to GM atrophy in areas associated with motor and cognitive functioning in areas involved in motor functioning and cognitive domains such as learning and memory.
Brain atrophy and clinical characteristics predicting SDMT performance in multiple sclerosis: A 10-year follow-up study
TLDR
This longitudinal study shows that baseline MRI-markers, demographic and clinical data can help predict worsening IPS and Identification of patients at risk of IPS decline is of importance as follow-up, treatment and rehabilitation can be optimized.
MRI correlates of disability progression in patients with CIS over 48 months
TLDR
Development of GM pathology and LVV enlargement are associated with SDP, and conversion to CDMS in patients with CIS over 48 months is dependent on the accumulation of new lesions, LVv enlargement and whole brain atrophy progression.
Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis
TLDR
Rate of BVL in patients during the fingolimod trials correlated with disease severity at baseline and new disease activity on study, and was associated with worsening disability.
Thalamic Atrophy Without Whole Brain Atrophy Is Associated With Absence of 2-Year NEDA in Multiple Sclerosis
TLDR
Patients with isolated thalamic atrophy were at a higher risk for not reaching 2-year NEDA-3 and for EDSS increase than patients with no identified brain atrophy, and a single measurement ofThalamic and whole brainatrophy could help identify patients needing most effective therapies from early on.
clinical and MRI outcomes in multiple sclerosis
TLDR
Rate of BVL in patients during the fingolimod trials correlated with disease severity at baseline and new disease activity on study, and was associated with worsening disability.
Brain atrophy and employment in multiple sclerosis patients: a 10-year follow-up study
TLDR
Atrophy of subcortical deep grey matter showed a stronger association to unemployment than atrophy of cortical volume during the follow-up, and to a lesser degree cortical volume, were significantly associated with unemployment throughout theFollow-up.
Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis.
TLDR
Atrophied brain T2 lesion volume is a robust MRI marker of MS disability progression and conversion into a secondary progressive disease course.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 52 REFERENCES
Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis
TLDR
The rate of ventricular enlargement seems to be even more strongly predictive of disease progression after medium term follow-up than whole brain atrophy rate, and also outperforms lesion measures.
Eight-year follow-up study of brain atrophy in patients with MS
TLDR
Atrophy rate during the original trial was the most significant MRI predictor of disability status at follow-up and the relation between atrophy progression and subsequent neurologic disability status suggests thatatrophy progression during RRMS is clinically relevant, Therefore, atrophy progress may be a useful marker for disease progression in clinical trials.
Brain atrophy and lesion load predict long term disability in multiple sclerosis
TLDR
This large multicentre study points to the complementary predictive value of atrophy and lesion volumes for predicting long term disability in MS.
Gray matter atrophy and disability progression in patients with early relapsing–remitting multiple sclerosis A 5-year longitudinal study
TLDR
PBVC and LVV showed the strongest ability to differentiate patients who presented 0 or >or=3 relapses in the Stable group, and decline in PBVC and GMV were predictive markers of disability deterioration.
Brain atrophy in clinically early relapsing-remitting multiple sclerosis.
TLDR
The results indicate that significant brain atrophy, affecting both grey and white matter, occurs early in the clinical course of multiple sclerosis.
Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study.
TLDR
Investigation of short-term changes in GM and WM volumes and the predictive value of demographic, clinical and radiological variables to gain a better understanding of the pathological substrate underlying these changes found SIENA and SPM-based methods appear to provide complementary information.
Evidence of early cortical atrophy in MS
TLDR
The extent of the changes suggests that neocortical GM pathology may occur early in the course of the disease in both RR and PP MS patients and contribute significantly to neurologic impairment.
Evolution of Cortical and Thalamus Atrophy and Disability Progression in Early Relapsing-Remitting MS during 5 Years
TLDR
SDP is associated with progression of cortical, central, and thalamic atrophy in early RRMS during 5 years and changes with time in whole-brain, cortical, lateral ventricle, thalamus, and total SDGM volume are shown.
Thalamic atrophy is associated with development of clinically definite multiple sclerosis.
TLDR
Measurement of thalamic atrophy and increase in ventricular size in CIS is associated with CDMS development and should be used in addition to the assessment of new T2 and CE lesions.
Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case–control study
TLDR
The study showed a different evolution of tissue compartment atrophy measures in patients with MS, with faster decline in cortical and deep GM regions, as well as periventricular WM regions, over a 5-year period.
...
1
2
3
4
5
...